This paper focuses on advances in prostatic cancer that occurred during the past year. Specific areas reviewed here are screening, radical surgery, locoregional disease, the no-therapy option, androgen-ablative therapy, prognostic factors, bone-specific therapy, hormone refractory disease, and prostate cancer biology.